Loss of heterozygosity at 7q31 in breast cancer: Results from an international collaborative study group

Genes Chromosomes and Cancer

Volumn 18, Issue 3, 1997, Pages 193-199

  Devilee, P ^a   Hermans, J ^a   Eyfjord J ^b   Borresen A L ^c   Lidereau, R ^d   Sobol, H ^e   Borg, A ^h   Cleton Jansen, A M ^a   Olah E ⁱ   Cohen, B B ^l   Scherneck, S ^j   Hamann, U ^k   Peterlin, B ^l   Caligo, M ^m   Bignon, Y J ^f   Maugard, Ch ^g   Andersen, T I ^c   Odegand A E M ^c   Bieche I ^d   Birnbaum, D ^e   Cornelisse, C J ^a   Sztan M ⁱ   Steel, M ^l   Seitz, S ^j   Logar, N ^l   Gulouh, R ^l   Ghimenti, C ^m   Bruelle, S ^f   Joalland, M P ^g   more..

^a LEIDEN UNIVERSITY   (Netherlands)

^b ICELANDIC CANCER SOCIETY   (Iceland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CENTRE RENÉ HUGUENIN   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CENTRE JEAN PERRIN   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^j MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l Tumor Genetik Max Delbrück Zentrum ^*

^m UNIVERSITY OF PISA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 7Q; CONTROLLED STUDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030891546     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Berx G, Cleton-Jansen AM, Nollet F, De Leeuw WJF, Van de Vijver MJ, Cornelisse C, Van Roy F (1995) E-cadherin is a tumour invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115.
2. Bièche I, Lidereau R (1995) Genetic alterations in breast cancer. Genes Chromosom Cancer 14:227-251.
3. Bièche I, Champeme M, Matifas F, Hacene K, Callahan R, Lidereau R (1992) Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339:139-143.
4. Bièche I, Champeme M, Marifas F, Cropp C, Callahan R, Lidereau R (1993) Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53:1990-1994.
5. Cleton-Jansen A, Moerland E, Kuipers-Dijkshoorn N, Callen D, Sutherland G, Hansen B, Devilee P, Cornelisse C (1994) At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosom Cancer 9:101-107.
6. Cornelis R, Devilee P, Van Vliet M, Kuipers-Dijkshoorn N, Kersenmaeker A, Bardoel A, Meera Khan P, Cornelisse C (1993) Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions. Oncogene 8:781-785.
7. Cornelis R, Van Vliet M, Vos C, Cleton-Jansen A, Van de Vijver M, Peterse H, Meera Khan P, Børresen A, Cornelisse C, Devilee P (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200-4206.
8. Cornelisse C, (1992) Loss of heterozygosity, chromosome 7q, and breast cancer. Lancet 339:1423.
9. Cropp C, Champeme M, Lidereau R, Callahan R (1993) Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res 53:5617-5619.
10. Deng G, Chen L, Schott D, Thor A, Bhargava V, Ljung B, Chew K, Smith H (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499-505.
11. Devilee P, Cornelisse C (1994) Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130.
12. Devilee P, Van Vliet M, Bardoel A, Kievits T, Kuipers-Dijkshoorn N, Pearson P, Cornelisse C (1991a) Frequent somatic imbalance of parental chromosomes 1 in human primary breast carcinoma. Cancer Res 51:1020-1025.
13. Devilee P, Van Vliet M, Van Sloun P, Kuipers-Dijkshoorn N, Hermans J, Pearson P, Cornelisse C (1991b) Allelotype of human breast carcinoma: A second major site for loss of heterozygosity is on chromosome 6q. Oncogene 6:1705-1711.
14. Devilee P, Van de Vijver M, Schuuring E, Cornelisse C (1994) Recent developments in the molecular genetics of human primary breast cancer. Crit Rev Oncogen 5:247-270.
15. Eeles R, Bartkova J, Lane D, Bartek J (1993) The role of TP53 in breast cancer development. Cancer Surv 18:57-75.
16. Kerangueven F, Noguchi T, Adélaïde J, Jacquemier J, Sobol H, Birnbaum D (1995) Allelic loss at markers of chromosomal band 7q31 is not a frequent event in human breast cancer. Oncol Rep 2:89-90.
17. Kirchweger R, Zeillinger R, Schneeberger C, Speiser P, Louason G, Theillet C (1994) Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer 56:193-199.
18. Knudson A (1989) Hereditary cancers: Clues to mechanisms of carcinogenesis. Br J Cancer 59:661-666.
19. Kuniyasu H, Yasui W, Yokozaki H, Akagi M, Kitahara K, Fujii K, Tahara E (1994) Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer 59:597-600.
20. Lalle P, De Latour M, Rio P, Bignon Y (1994) Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in familial context. Oncogens 9:437-442.
21. Larsson C, Byström C, Skoog L, Rotstein S, Nordenskjöld M (1990) Genomic alterations in human breast carcinomas. Genes Chromosom Cancer 2:191-197.
22. Lasko D, Cavenee W, Nordenskjöld M (1991) Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25:281-314.
23. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
24. Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y (1991) Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 51:5794-5799.
25. Sheng ZM, Marchetti A, Buttitta F, Champeme MH, Campani D, Bistocchi M, Lidereau R, Callahan R (1996) Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 73:144-147.
26. Taguchi T, Testa JR, Papas TS, Schweinfest C (1994) Localization of a candidate tumor suppressor gene (DRA) to 7q22-q31.1 by fluorescence in situ hybridization. Genomics 20:146-147.
27. Takahasi S, Shan A, Ritland S, DeLacey K, Bostwick D, Lieber M, Thibodeau S, Jenkins R (1995) Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55:4114-4119.
28. Takita K, Sato T, Miyagi M, Watatani M, Akiyama F, Sakamoto G, Kasumi F, Abe R, Nakamura Y (1992) Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res 52:3914-3917.
29. Weber J, Wong C (1993) Mutation of human short tandem repeats. Hum Mol Genet 2:1123-1128.
30. Weiss SE, Tartter PI, Ahmed SA, Brower ST, Brusco C, Bossolt K, Amberson JB, Bratton J (1995) Ethnic differences in risk and prognostic factors for breast cancer. Cancer 76:268-274.
31. Winqvist R, Hampton G, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H, Taskinen P, Evans G, Wright F, Newsham I, Cavenee W (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55:2660-2664.
32. Zenklusen J, Bieche I, Lidereau R, Conti C (1994a) (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91:12155-12158.
33. Zenklusen J, Thompson J, Troncoso P, Kagan J, Conti C (1994b) Loss of heterozygosity in human primary prostate carcinomas: A possible tumor suppressor gene at 7q311. Cancer Res 54:6370-6373.
34. Zenklusen J, Thompson J, Klein-Szanto A, Conti C (1995a) Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: Evidence for a broad range tumor suppressor gene. Cancer Res 55:1347-1350.
35. Zenklusen J, Weitzel J, Ball H, Conti C (1995b) Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogenc 11:359-363.